MZEEarnings•globenewswire•
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Sentiment:Negative (30)
Summary
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire